Fresh2 Group Limited

OTCPK:FREH.Y Stock Report

Market Cap: US$222.0

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Fresh2 Group Balance Sheet Health

Financial Health criteria checks 0/6

Insufficient data to determine the health of Fresh2 Group

Key information

n/a

Debt to equity ratio

n/a

Debt

Interest coverage ration/a
Cashn/a
Equityn/a
Total liabilitiesn/a
Total assetsn/a

Recent financial health updates

Recent updates

Seeking Alpha • Oct 18

AnPac Bio announces plan to implement ADS ratio change

AnPac Bio (NASDAQ:ANPC) plans to change the ratio of the company’s American Depositary Shares to its Class A ordinary shares from one ADS representing one Class A ordinary share to one  ADS representing twenty Class A ordinary shares. The change in the ADS ratio is expected to take place on November 4, 2022. For the company’s ADS holders, the change in the ADS ratio will have the same effect as a one-for-twenty reverse ADS split.  The ADSs will continue to be traded on Nasdaq under the symbol “ANPC.” There will be no change to the company’s Class A ordinary shares. Shares are up 1.7% premarket.
Seeking Alpha • Oct 03

AnPac Bio-Medical Science announces management changes

AnPac Bio-Medical Science (NASDAQ:ANPC) announces that Mr. Haohan Xu has been appointed as a director of the board of directors, Co-Chairperson of the Board and Co-CEO of the company. Mr. Xu is the CEO of Apifiny Group Ms. Xiaoyu Li has been appointed as a director of the Board and as CFO. Ms. Li has extensive experience in investor relations and investment. From May 2018 to August 2021, Ms. Li served as a director of Mercurity Fintech Holding Inc., where Ms. Li previously worked at the investor relations department from 2012 to 2013. Mr. Tianruo (Robert) Pu has been appointed as a director of the
Seeking Alpha • Sep 27

AnPac Bio-Medical Science signed equity investment totaling $3.67M with new investor Group

AnPac Bio-Medical Science (NASDAQ:ANPC) and a group of nine institutional and individual investors have signed legally binding pacts for the investment in the company of ~$3.67M to purchase 36.7M of the company’s Class A shares. It is expected that the investment will be completed in late September 2022.
Seeking Alpha • Aug 05

AnPac Bio appoints Yuyang Cui as co-chief executive officer

AnPac Bio-Medical (NASDAQ:ANPC) said it had appointed Yuyang Cui as co-chairman of the board and co-chief executive officer of the company. Jiawen Kang has been appointed as a member of the board of directors of the Company and a member of the Audit Committee and Nominating Committee.
Analysis Article • Dec 11

Industry Analysts Just Upgraded Their AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) Revenue Forecasts By 55%

AnPac Bio-Medical Science Co., Ltd. ( NASDAQ:ANPC ) shareholders will have a reason to smile today, with the analysts...

Financial Position Analysis

Short Term Liabilities: Insufficient data to determine if FREH.Y's short term assets cover its short term liabilities.

Long Term Liabilities: Insufficient data to determine if FREH.Y's short term assets cover its long term liabilities.

Debt to Equity History and Analysis

Debt Level: Insufficient data to calculate FREH.Y's net debt to equity ratio to determine if it is satisfactory.

Reducing Debt: Insufficient data to determine if FREH.Y's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: Insufficient data to determine if FREH.Y's debt is well covered by operating cash flow.

Interest Coverage: Insufficient data to determine if FREH.Y's interest payments on its debt are well covered by EBIT.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/02 21:25
End of Day Share Price 2025/11/20 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Fresh2 Group Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Theodore O'NeillLitchfield Hills Research, LLC